News | January 21, 2026
iRegene’s Parkinson’s therapy gains FDA designation
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The study evaluated patients with stage III/IV melanoma after complete tumor resection
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
